109 related articles for article (PubMed ID: 20501805)
1. Endocytosis of PEGylated agents enhances cancer imaging and anticancer efficacy.
Chuang KH; Wang HE; Chen FM; Tzou SC; Cheng CM; Chang YC; Tseng WL; Shiea J; Lin SR; Wang JY; Chen BM; Roffler SR; Cheng TL
Mol Cancer Ther; 2010 Jun; 9(6):1903-12. PubMed ID: 20501805
[TBL] [Abstract][Full Text] [Related]
2. Selective Delivery of PEGylated Compounds to Tumor Cells by Anti-PEG Hybrid Antibodies.
Tung HY; Su YC; Chen BM; Burnouf PA; Huang WC; Chuang KH; Yan YT; Cheng TL; Roffler SR
Mol Cancer Ther; 2015 Jun; 14(6):1317-26. PubMed ID: 25852063
[TBL] [Abstract][Full Text] [Related]
3. Bispecific antibody (HER2 × mPEG) enhances anti-cancer effects by precise targeting and accumulation of mPEGylated liposomes.
Chen IJ; Cheng YA; Ho KW; Lin WW; Cheng KW; Lu YC; Hsieh YC; Huang CC; Chuang CH; Chen FM; Su YC; Roffler SR; Cheng TL
Acta Biomater; 2020 Jul; 111():386-397. PubMed ID: 32417267
[TBL] [Abstract][Full Text] [Related]
4. Pre-existing anti-polyethylene glycol antibody reduces the therapeutic efficacy and pharmacokinetics of PEGylated liposomes.
Hsieh YC; Wang HE; Lin WW; Roffler SR; Cheng TC; Su YC; Li JJ; Chen CC; Huang CH; Chen BM; Wang JY; Cheng TL; Chen FM
Theranostics; 2018; 8(11):3164-3175. PubMed ID: 29896310
[No Abstract] [Full Text] [Related]
5. Enhancement Effect of a Variable Topology of a Membrane-Tethered Anti-Poly(ethylene glycol) Antibody on the Sensitivity for Quantifying PEG and PEGylated Molecules.
Lin WW; Cheng YA; Kao CH; Roffler SR; Lee YC; Chen BM; Hsieh YC; Chen IJ; Huang BC; Wang YT; Tung YC; Huang MY; Chen FM; Cheng TL
Anal Chem; 2017 Jun; 89(11):6082-6090. PubMed ID: 28485140
[TBL] [Abstract][Full Text] [Related]
6. Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer.
Deshpande P; Jhaveri A; Pattni B; Biswas S; Torchilin V
Drug Deliv; 2018 Nov; 25(1):517-532. PubMed ID: 29433357
[TBL] [Abstract][Full Text] [Related]
7. The effect of liposomal size on the targeted delivery of doxorubicin to Integrin αvβ3-expressing tumor endothelial cells.
Kibria G; Hatakeyama H; Ohga N; Hida K; Harashima H
Biomaterials; 2013 Jul; 34(22):5617-27. PubMed ID: 23623323
[TBL] [Abstract][Full Text] [Related]
8. Engineering Chimeric Receptors To Investigate the Size- and Rigidity-Dependent Interaction of PEGylated Nanoparticles with Cells.
Huang WC; Burnouf PA; Su YC; Chen BM; Chuang KH; Lee CW; Wei PK; Cheng TL; Roffler SR
ACS Nano; 2016 Jan; 10(1):648-62. PubMed ID: 26741147
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy.
Lv S; Li M; Tang Z; Song W; Sun H; Liu H; Chen X
Acta Biomater; 2013 Dec; 9(12):9330-42. PubMed ID: 23958784
[TBL] [Abstract][Full Text] [Related]
10. Anticancer Efficacy of the Combination of Berberine and PEGylated Liposomal Doxorubicin in Meth A Sarcoma-Bearing Mice.
Yahuafai J; Asai T; Oku N; Siripong P
Biol Pharm Bull; 2018; 41(7):1103-1106. PubMed ID: 29962406
[TBL] [Abstract][Full Text] [Related]
11. Safety and tumor tissue accumulation of pegylated graphene oxide nanosheets for co-delivery of anticancer drug and photosensitizer.
Miao W; Shim G; Lee S; Lee S; Choe YS; Oh YK
Biomaterials; 2013 Apr; 34(13):3402-10. PubMed ID: 23380350
[TBL] [Abstract][Full Text] [Related]
12. Development of a universal anti-polyethylene glycol reporter gene for noninvasive imaging of PEGylated probes.
Chuang KH; Wang HE; Cheng TC; Tzou SC; Tseng WL; Hung WC; Tai MH; Chang TK; Roffler SR; Cheng TL
J Nucl Med; 2010 Jun; 51(6):933-41. PubMed ID: 20484433
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor effect via passive anti-angiogenesis of PEGylated liposomes encapsulating doxorubicin in drug resistant tumors.
Kibria G; Hatakeyama H; Sato Y; Harashima H
Int J Pharm; 2016 Jul; 509(1-2):178-187. PubMed ID: 27234700
[TBL] [Abstract][Full Text] [Related]
14. In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells.
Ogawara K; Un K; Tanaka K; Higaki K; Kimura T
J Control Release; 2009 Jan; 133(1):4-10. PubMed ID: 18840484
[TBL] [Abstract][Full Text] [Related]
15. Low-toxicity transferrin-guided polymersomal doxorubicin for potent chemotherapy of orthotopic hepatocellular carcinoma in vivo.
Wei Y; Gu X; Cheng L; Meng F; Storm G; Zhong Z
Acta Biomater; 2019 Jul; 92():196-204. PubMed ID: 31102765
[TBL] [Abstract][Full Text] [Related]
16. Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines.
Elbayoumi TA; Torchilin VP
Eur J Pharm Sci; 2007 Nov; 32(3):159-68. PubMed ID: 17707615
[TBL] [Abstract][Full Text] [Related]
17. Intracellular fate of LDL receptor family members depends on the cooperation between their ligand-binding and EGF domains.
Van Hoof D; Rodenburg KW; Van der Horst DJ
J Cell Sci; 2005 Mar; 118(Pt 6):1309-20. PubMed ID: 15741231
[TBL] [Abstract][Full Text] [Related]
18. Low-density lipoprotein receptor-mediated endocytosis of PEGylated nanoparticles in rat brain endothelial cells.
Kim HR; Gil S; Andrieux K; Nicolas V; Appel M; Chacun H; Desmaële D; Taran F; Georgin D; Couvreur P
Cell Mol Life Sci; 2007 Feb; 64(3):356-64. PubMed ID: 17256088
[TBL] [Abstract][Full Text] [Related]
19. Initial hepatic removal of chylomicron remnants is unaffected but endocytosis is delayed in mice lacking the low density lipoprotein receptor.
Herz J; Qiu SQ; Oesterle A; DeSilva HV; Shafi S; Havel RJ
Proc Natl Acad Sci U S A; 1995 May; 92(10):4611-5. PubMed ID: 7753850
[TBL] [Abstract][Full Text] [Related]
20. The complex of the insect LDL receptor homolog, lipophorin receptor, LpR, and its lipoprotein ligand does not dissociate under endosomal conditions.
Roosendaal SD; Kerver J; Schipper M; Rodenburg KW; Van der Horst DJ
FEBS J; 2008 Apr; 275(8):1751-66. PubMed ID: 18331356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
